Two vaccines are on the horizon for the prevention of
Lyme disease, the most common vector-borne illness in the US and Europe. This review describes the pathogenesis and clinical illness of
Lyme disease, as well as the sequence of events that led to the development of these novel vaccines. The results of the most recent Phase III human trials are reported.